LeonaBio, Inc.
LeonaBio, Inc.
Your view on LONA
Overview
What the company does, where it operates, and who runs it.
About LeonaBio, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Mark J. Litton
- Headquarters
- 18706 North Creek Parkway, Bothell, WA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Mark J. Litton
- Headquarters
- 18706 North Creek Parkway, Bothell, WA, US
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions.
The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders.
Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for LeonaBio, Inc., and the rating behind it. LONA last traded at $4.97; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for LeonaBio, Inc.. Starting points for LeonaBio, Inc.: EPS -$33.08, beta 2.12 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for LeonaBio, Inc.. LeonaBio, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for LeonaBio, Inc.. Trailing twelve-month EPS for LeonaBio, Inc. stands at -$33.08. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for LeonaBio, Inc.. LeonaBio, Inc. has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
LeonaBio, Inc. valued side by side against its closest peers. LeonaBio, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold LeonaBio, Inc., and how their positions are changing. At a $19.6M market value, institutional positions materially move LeonaBio, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by LeonaBio, Inc. executives and directors. Shares of LeonaBio, Inc. have traded between $4.25 and $11.91 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming LeonaBio, Inc.. LeonaBio, Inc. is a $19.6M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming LeonaBio, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for LeonaBio, Inc.. Coverage tracks LeonaBio, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.